/**
 * Neuro-Epi Trial Database -- Batch 5
 * Additional landmark trials in stroke, cardiology, and neurovascular disease.
 * Covers thrombectomy, thrombolysis, anticoagulation, ICH, SAH, carotid, and vascular prevention.
 */
(function() {
    if (!window.TrialDatabase) window.TrialDatabase = { trials: [] };
    var T = window.TrialDatabase.trials;
    T.push(

    // ==========================================
    // THROMBECTOMY — ADDITIONAL
    // ==========================================
    {
        name: 'THRACE',
        fullTitle: 'Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke',
        year: 2016,
        category: 'thrombectomy',
        journal: 'The Lancet Neurology',
        pmid: '27567239',
        doi: '10.1016/S1474-4422(16)30177-6',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 414,
        population: 'Acute ischemic stroke with proximal anterior circulation occlusion (ICA or M1), NIHSS >=10, within 5 hours of onset, treated with IV tPA',
        intervention: 'IV tPA plus endovascular thrombectomy',
        comparator: 'IV tPA alone',
        primaryOutcome: 'mRS 0-2 at 3 months: 53% vs 42%; OR 1.55 (1.05-2.30), p=0.028',
        keyResult: 'Thrombectomy after IV tPA improved functional independence by 11 absolute percentage points.',
        conclusion: 'Sixth positive thrombectomy trial, confirming benefit of combined IV tPA and thrombectomy in anterior LVO stroke. Contributed to the robust evidence base supporting thrombectomy as standard of care.',
        landmark: true,
        tags: ['thrombectomy', 'LVO', 'bridging', 'IV tPA', 'French']
    },
    {
        name: 'THERAPY',
        fullTitle: 'The Randomized, Concurrent Controlled Trial to Assess the Penumbra System\'s Safety and Effectiveness in the Treatment of Acute Stroke',
        year: 2016,
        category: 'thrombectomy',
        journal: 'International Journal of Stroke',
        pmid: '26763029',
        doi: '10.1177/1747493015609632',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 108,
        population: 'Acute ischemic stroke with large vessel occlusion and clot length >=8 mm on CTA, within 8 hours, treated with IV tPA',
        intervention: 'IV tPA plus endovascular thrombectomy with Penumbra aspiration system',
        comparator: 'IV tPA alone',
        primaryOutcome: 'mRS 0-2 at 90 days: 38% vs 30%; OR 1.4 (0.6-3.3), p=0.44. Trial stopped early due to results of other thrombectomy trials.',
        keyResult: 'Not statistically significant due to early termination; favorable trend toward thrombectomy.',
        conclusion: 'Stopped early after positive results from MR CLEAN, ESCAPE, EXTEND-IA, SWIFT PRIME, and REVASCAT. Though underpowered, directionally consistent with the positive thrombectomy evidence.',
        landmark: false,
        tags: ['thrombectomy', 'LVO', 'aspiration', 'Penumbra', 'stopped early']
    },
    {
        name: 'PISTE',
        fullTitle: 'Pragmatic Ischaemic Stroke Thrombectomy Evaluation',
        year: 2017,
        category: 'thrombectomy',
        journal: 'Journal of Neurology, Neurosurgery and Psychiatry',
        pmid: '27899493',
        doi: '10.1136/jnnp-2016-314117',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 65,
        population: 'Acute ischemic stroke with anterior circulation large vessel occlusion within 6 hours, treated with IV tPA',
        intervention: 'IV tPA plus endovascular thrombectomy',
        comparator: 'IV tPA alone',
        primaryOutcome: 'mRS 0-2 at 90 days: 51% vs 40%; adjusted OR 2.12 (0.65-6.94), p=0.21. Stopped early after other positive trials.',
        keyResult: 'Favorable trend for thrombectomy but underpowered due to early termination.',
        conclusion: 'UK pragmatic trial stopped early for external evidence. Contributed to the broader evidence base and facilitated the adoption of thrombectomy in UK stroke services.',
        landmark: false,
        tags: ['thrombectomy', 'LVO', 'pragmatic', 'UK', 'stopped early']
    },
    {
        name: 'SKIP',
        fullTitle: 'Direct Mechanical Thrombectomy in Acute LVO Stroke',
        year: 2022,
        category: 'thrombectomy',
        journal: 'JAMA Neurology',
        pmid: '35044424',
        doi: '10.1001/jamaneurol.2021.5131',
        design: 'Phase 3 RCT, open-label, noninferiority',
        n: 204,
        population: 'Acute anterior circulation LVO stroke within 4.5 hours eligible for both IV tPA and thrombectomy, in Japan',
        intervention: 'Direct thrombectomy without prior IV tPA',
        comparator: 'IV tPA followed by thrombectomy (bridging)',
        primaryOutcome: 'mRS 0-2 at 90 days: 59.4% vs 57.3%; absolute difference 2.1% (-10.4 to 14.5). Noninferiority not established.',
        keyResult: 'Direct thrombectomy failed to demonstrate noninferiority to bridging therapy.',
        conclusion: 'Fourth major trial failing to show noninferiority of direct thrombectomy, further supporting continued IV tPA bridging before thrombectomy when eligible.',
        landmark: false,
        tags: ['thrombectomy', 'direct', 'bridging', 'noninferiority', 'Japanese']
    },
    {
        name: 'RESCUE-Japan 2',
        fullTitle: 'Recovery by Endovascular Salvage for Cerebral Ultra-Acute Embolism Japan 2',
        year: 2023,
        category: 'thrombectomy',
        journal: 'New England Journal of Medicine',
        pmid: '37212444',
        doi: '10.1056/NEJMoa2301119',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 203,
        population: 'Acute medium vessel occlusion (M2, M3, A2, A3, P2, P3) stroke within 24 hours',
        intervention: 'Endovascular thrombectomy plus medical management',
        comparator: 'Medical management alone',
        primaryOutcome: 'mRS 0-2 at 90 days: 58.6% vs 31.1%; adjusted OR 3.19 (1.72-5.93), p<0.001',
        keyResult: 'Thrombectomy nearly doubled functional independence rates in medium vessel occlusion stroke.',
        conclusion: 'First positive RCT for thrombectomy in medium vessel occlusions, expanding the indication beyond proximal large vessel occlusions. Practice-changing for stroke care.',
        landmark: true,
        tags: ['thrombectomy', 'medium vessel occlusion', 'M2', 'expanded indication']
    },

    // ==========================================
    // THROMBOLYSIS — ADDITIONAL
    // ==========================================
    {
        name: 'SITS-MOST',
        fullTitle: 'Safe Implementation of Thrombolysis in Stroke-Monitoring Study',
        year: 2007,
        category: 'thrombolysis',
        journal: 'The Lancet',
        pmid: '17258671',
        doi: '10.1016/S0140-6736(07)60171-8',
        design: 'Prospective observational cohort (post-marketing safety study)',
        n: 6483,
        population: 'Acute ischemic stroke patients treated with IV alteplase within 3 hours in routine clinical practice across Europe',
        intervention: 'IV alteplase 0.9 mg/kg within 3 hours per EU marketing authorization',
        comparator: 'Compared with pooled RCT data (NINDS, ECASS, ATLANTIS)',
        primaryOutcome: 'Symptomatic ICH within 24 hours (SITS-MOST definition): 1.7%; mortality at 3 months: 11.3%; mRS 0-1 at 3 months: 54.8%',
        keyResult: 'Real-world safety and efficacy comparable to randomized trial results.',
        conclusion: 'Landmark post-marketing study demonstrating that IV alteplase can be administered safely in routine clinical practice with outcomes comparable to controlled trials. Facilitated broader adoption of thrombolysis across Europe.',
        landmark: true,
        tags: ['alteplase', 'tPA', 'post-marketing', 'safety', 'observational', 'European']
    },
    {
        name: 'ECASS I',
        fullTitle: 'European Cooperative Acute Stroke Study',
        year: 1995,
        category: 'thrombolysis',
        journal: 'JAMA',
        pmid: '7666831',
        doi: '10.1001/jama.1995.03530180023027',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 620,
        population: 'Acute ischemic stroke within 6 hours of symptom onset',
        intervention: 'IV alteplase 1.1 mg/kg (higher dose than subsequent trials)',
        comparator: 'Placebo',
        primaryOutcome: 'Barthel Index >=95 at 90 days: 35.7% vs 29.3%; p=0.066 (ITT not significant). Target population analysis: p=0.035.',
        keyResult: 'Primary ITT analysis was negative; post-hoc target population analysis showed benefit.',
        conclusion: 'First large European thrombolysis trial. Though the primary ITT analysis was negative, the higher dose (1.1 mg/kg) caused excess hemorrhage. Led to dose reduction to 0.9 mg/kg for subsequent ECASS II and III trials.',
        landmark: true,
        tags: ['alteplase', 'tPA', 'dose-finding', '6-hour window', 'European']
    },
    {
        name: 'NINDS Part 2',
        fullTitle: 'National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Part 2',
        year: 1995,
        category: 'thrombolysis',
        journal: 'New England Journal of Medicine',
        pmid: '7477192',
        doi: '10.1056/NEJM199512143332401',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 333,
        population: 'Acute ischemic stroke within 3 hours, Part 2 focused on 3-month clinical outcomes',
        intervention: 'IV alteplase 0.9 mg/kg (10% bolus, 90% over 60 minutes)',
        comparator: 'Placebo',
        primaryOutcome: 'Favorable outcome across four scales (mRS, Barthel, Glasgow, NIHSS) at 90 days: OR 1.7 (1.2-2.6), p=0.008',
        keyResult: 'Global benefit across multiple outcome measures with 30% relative increase in excellent outcomes.',
        conclusion: 'Part 2 of the NINDS trial focused on clinical outcomes and confirmed that alteplase significantly improved functional outcomes at 3 months. Together with Part 1, led to FDA approval of alteplase for acute ischemic stroke.',
        landmark: true,
        tags: ['alteplase', 'tPA', '3-hour window', 'FDA approval', 'landmark']
    },

    // ==========================================
    // ANTICOAGULATION — ADDITIONAL
    // ==========================================
    {
        name: 'COMMANDER HF',
        fullTitle: 'A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction, or Stroke in Participants with Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure',
        year: 2018,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '30415602',
        doi: '10.1056/NEJMoa1808848',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 5022,
        population: 'Heart failure with reduced ejection fraction (EF <=40%), coronary artery disease, no atrial fibrillation, recent worsening heart failure',
        intervention: 'Rivaroxaban 2.5 mg twice daily',
        comparator: 'Placebo',
        primaryOutcome: 'Composite of death, MI, or stroke: 25.0% vs 26.2%; HR 0.94 (0.84-1.05), p=0.27',
        keyResult: 'Low-dose rivaroxaban did not reduce death, MI, or stroke in heart failure patients without AF.',
        conclusion: 'Unlike COMPASS (which showed benefit in stable atherosclerosis), low-dose rivaroxaban did not benefit HF patients without AF. Suggests that the thrombotic mechanism in HF differs from stable atherosclerosis.',
        landmark: false,
        tags: ['rivaroxaban', 'heart failure', 'coronary artery disease', 'negative trial']
    },
    {
        name: 'CRYSTAL AF',
        fullTitle: 'Cryptogenic Stroke and Underlying Atrial Fibrillation',
        year: 2014,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '24946063',
        doi: '10.1056/NEJMoa1309697',
        design: 'Prospective RCT, open-label',
        n: 441,
        population: 'Cryptogenic stroke or TIA within 90 days, age >=40, with no AF detected on standard monitoring',
        intervention: 'Insertable cardiac monitor (Reveal XT) plus conventional follow-up',
        comparator: 'Conventional follow-up alone (ECG, Holter)',
        primaryOutcome: 'Detection of AF (>30 seconds) at 6 months: 8.9% vs 1.4%; HR 6.4 (1.9-21.7), p<0.001. At 12 months: 12.4% vs 2.0%.',
        keyResult: 'Insertable cardiac monitors detected AF 6 times more often than conventional monitoring after cryptogenic stroke.',
        conclusion: 'Landmark trial establishing that prolonged cardiac monitoring with implantable loop recorders dramatically increases AF detection after cryptogenic stroke. Changed practice for post-stroke cardiac workup and informed guidelines recommending prolonged monitoring.',
        landmark: true,
        tags: ['atrial fibrillation', 'cryptogenic stroke', 'cardiac monitoring', 'implantable loop recorder', 'landmark']
    },
    {
        name: 'EMBRACE',
        fullTitle: '30-Day Cardiac Event Monitor Belt for Recording Atrial Fibrillation After a Cerebral Ischemic Event',
        year: 2014,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '24946062',
        doi: '10.1056/NEJMoa1313975',
        design: 'Phase 3 RCT, open-label',
        n: 572,
        population: 'Cryptogenic ischemic stroke or TIA within 6 months, age >=55, no known AF, no AF on initial 24-hour Holter',
        intervention: '30-day ambulatory cardiac event monitor',
        comparator: 'Repeat 24-hour Holter monitor',
        primaryOutcome: 'AF detection (>=30 seconds) within 90 days: 16.1% vs 3.2%; absolute difference 12.9% (8.0-17.6), p<0.001',
        keyResult: '30-day cardiac monitoring detected AF five times more often than standard 24-hour Holter.',
        conclusion: 'Demonstrated that prolonged outpatient cardiac monitoring after cryptogenic stroke substantially increases detection of AF. Together with CRYSTAL AF, established the standard for extended cardiac monitoring in stroke workup.',
        landmark: true,
        tags: ['atrial fibrillation', 'cryptogenic stroke', 'cardiac monitoring', '30-day monitor', 'landmark']
    },
    {
        name: 'ASSERT',
        fullTitle: 'Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial',
        year: 2012,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '22236222',
        doi: '10.1056/NEJMoa1007753',
        design: 'Prospective cohort study with pacemaker-detected AF',
        n: 2580,
        population: 'Patients >=65 years with hypertension and a recently implanted dual-chamber pacemaker or ICD, no history of AF',
        intervention: 'Continuous pacemaker-based monitoring for subclinical atrial tachyarrhythmias (>190 bpm for >6 min)',
        comparator: 'No comparator (observational with stroke outcome)',
        primaryOutcome: 'Subclinical atrial tachyarrhythmias detected in 10.1% at 3 months and 34.7% at 2.5 years. Subclinical AT was associated with ischemic stroke or systemic embolism: HR 2.49 (1.28-4.85), p=0.007.',
        keyResult: 'Subclinical AF episodes detected by pacemaker were associated with 2.5-fold increased stroke risk.',
        conclusion: 'Established that device-detected subclinical atrial tachyarrhythmias are common and associated with increased stroke risk. Raised the question of whether to anticoagulate for subclinical AF, leading to NOAH-AFNET 6 and ARTESIA.',
        landmark: true,
        tags: ['atrial fibrillation', 'subclinical AF', 'pacemaker', 'stroke risk', 'landmark']
    },
    {
        name: 'NOAH-AFNET 6',
        fullTitle: 'Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial High-Rate Episodes',
        year: 2023,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '37622677',
        doi: '10.1056/NEJMoa2303062',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 2536,
        population: 'Patients with device-detected subclinical atrial tachyarrhythmias (AHRE >=6 min, no clinical AF) and at least one stroke risk factor (age >=65 plus >=1 additional CHA2DS2-VASc component)',
        intervention: 'Edoxaban 60 mg daily (or 30 mg with dose-reduction criteria)',
        comparator: 'Placebo (or aspirin if previously prescribed)',
        primaryOutcome: 'Composite of cardiovascular death, stroke, or systemic embolism: 3.2% vs 4.0% per year; HR 0.81 (0.60-1.08), p=0.15. Stopped early for futility.',
        keyResult: 'Edoxaban did not significantly reduce cardiovascular events in device-detected subclinical AF.',
        conclusion: 'Anticoagulation for device-detected subclinical AF did not significantly reduce stroke or cardiovascular events. Challenged the assumption that subclinical AF requires the same treatment as clinical AF. Along with ARTESIA, informed a nuanced approach.',
        landmark: true,
        tags: ['edoxaban', 'subclinical AF', 'device-detected', 'negative trial', 'futility']
    },
    {
        name: 'ARTESIA',
        fullTitle: 'Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation',
        year: 2023,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '37622678',
        doi: '10.1056/NEJMoa2310234',
        design: 'Phase 3 RCT, double-blind, double-dummy',
        n: 4012,
        population: 'Patients >=55 years with device-detected subclinical AF (6 min to 24 hours, no clinical AF) and CHA2DS2-VASc >=3',
        intervention: 'Apixaban 5 mg twice daily (or 2.5 mg with dose-reduction criteria)',
        comparator: 'Aspirin 81 mg daily',
        primaryOutcome: 'Stroke or systemic embolism: 0.78% vs 1.24% per year; HR 0.63 (0.45-0.88), p=0.007',
        keyResult: 'Apixaban reduced stroke by 37% compared to aspirin in subclinical AF.',
        conclusion: 'Apixaban reduced stroke risk in device-detected subclinical AF, but the absolute benefit was modest (0.46%/year) and major bleeding was increased. Together with NOAH-AFNET 6, established that subclinical AF carries lower stroke risk than clinical AF and treatment decisions require careful risk-benefit assessment.',
        landmark: true,
        tags: ['apixaban', 'subclinical AF', 'device-detected', 'positive trial', 'aspirin']
    },
    {
        name: 'RESTART',
        fullTitle: 'REstart or STop Antithrombotics Randomised Trial',
        year: 2019,
        category: 'ich',
        journal: 'The Lancet',
        pmid: '31128924',
        doi: '10.1016/S0140-6736(19)30840-2',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment (PROBE)',
        n: 537,
        population: 'Survivors of spontaneous or anticoagulant-associated intracerebral hemorrhage who had been taking antithrombotic therapy before ICH and had a vascular indication for antithrombotics',
        intervention: 'Restart antiplatelet therapy (aspirin, clopidogrel, or dipyridamole)',
        comparator: 'Avoid antiplatelet therapy',
        primaryOutcome: 'Recurrent symptomatic ICH: 4% (restart) vs 9% (avoid); adjusted HR 0.51 (0.25-1.03), p=0.060',
        keyResult: 'Restarting antiplatelets after ICH was associated with a non-significant trend toward fewer recurrent ICH events.',
        conclusion: 'Restarting antiplatelet therapy after ICH did not increase and may reduce recurrent ICH, while potentially preventing ischemic vascular events. Challenged the dogma that antiplatelets must be permanently stopped after ICH.',
        landmark: true,
        tags: ['ICH', 'antiplatelet', 'restart', 'secondary prevention', 'practice-changing']
    },

    // ==========================================
    // STROKE SYSTEMS / WORKFLOW
    // ==========================================
    {
        name: 'DAWN Late',
        fullTitle: 'DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention — Final Results',
        year: 2023,
        category: 'thrombectomy',
        journal: 'Stroke',
        pmid: '36883261',
        doi: '10.1161/STROKEAHA.122.042345',
        design: 'Phase 3 RCT, long-term follow-up of DAWN trial',
        n: 206,
        population: 'Original DAWN trial cohort followed to 24 months',
        intervention: 'Thrombectomy (Trevo stent retriever) + standard care',
        comparator: 'Standard care alone',
        primaryOutcome: 'mRS 0-2 at 24 months: 52% vs 18%; adjusted difference 33 percentage points',
        keyResult: 'Thrombectomy benefit in the late window was durable at 2 years with no catch-up in the control group.',
        conclusion: 'Long-term follow-up confirmed that the dramatic benefit of late-window thrombectomy is sustained at 2 years, with no convergence of outcomes. Reinforced that imaging-selected late-window patients derive lasting benefit.',
        landmark: false,
        tags: ['thrombectomy', 'late window', 'long-term follow-up', 'durability']
    },
    {
        name: 'ESCAPE-NEXT',
        fullTitle: 'Endovascular Treatment and Nerinetide for Acute Ischemic Stroke',
        year: 2024,
        category: 'neuroprotection',
        journal: 'The Lancet',
        pmid: '38880092',
        doi: '10.1016/S0140-6736(24)00975-9',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 1028,
        population: 'Acute ischemic stroke with large vessel occlusion undergoing endovascular thrombectomy, NOT receiving IV alteplase',
        intervention: 'Nerinetide (NA-1) 2.6 mg/kg IV before thrombectomy',
        comparator: 'Placebo before thrombectomy',
        primaryOutcome: 'mRS 0-2 at 90 days: 59.0% vs 55.6%; adjusted OR 1.18 (0.92-1.52), p=0.20',
        keyResult: 'Nerinetide did not significantly improve functional outcomes even without alteplase co-administration.',
        conclusion: 'Follow-up to ESCAPE-NA1 testing nerinetide without the confounding alteplase interaction. Despite the rationale, nerinetide failed to improve outcomes, continuing the long history of failed neuroprotection trials.',
        landmark: false,
        tags: ['neuroprotection', 'nerinetide', 'PSD-95', 'thrombectomy', 'negative trial']
    },

    // ==========================================
    // VASCULAR PREVENTION — ADDITIONAL
    // ==========================================
    {
        name: 'LACI-2',
        fullTitle: 'LACunar Intervention Trial 2',
        year: 2023,
        category: 'secondary-prevention',
        journal: 'European Stroke Journal',
        pmid: '37021199',
        doi: '10.1177/23969873231164040',
        design: 'Phase 2 RCT, open-label, factorial',
        n: 363,
        population: 'Non-disabling lacunar ischemic stroke within 3 months, confirmed on MRI',
        intervention: 'Isosorbide mononitrate 25 mg twice daily and/or cilostazol 100 mg twice daily, in factorial design',
        comparator: 'No isosorbide mononitrate and/or no cilostazol, plus guideline medical therapy',
        primaryOutcome: 'Feasibility: retention >75%, adherence >80% at 12 months. Achieved: 80% retention, 67% adherence.',
        keyResult: 'Feasibility targets met for retention but not adherence; safety signals acceptable.',
        conclusion: 'Feasibility trial for novel small vessel disease treatments. Isosorbide mononitrate and cilostazol were reasonably well tolerated in lacunar stroke patients. Informs the design of a definitive phase 3 trial targeting cerebral small vessel disease.',
        landmark: false,
        tags: ['lacunar stroke', 'small vessel disease', 'isosorbide mononitrate', 'cilostazol', 'feasibility']
    },
    {
        name: 'CONVINCE',
        fullTitle: 'Colchicine for Prevention of Vascular Inflammation in Non-Cardioembolic Stroke',
        year: 2024,
        category: 'secondary-prevention',
        journal: 'European Heart Journal',
        pmid: '39217474',
        doi: '10.1093/eurheartj/ehae545',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment (PROBE)',
        n: 3154,
        population: 'Non-cardioembolic ischemic stroke or high-risk TIA within 30 days',
        intervention: 'Colchicine 0.5 mg daily plus guideline-based secondary prevention',
        comparator: 'Guideline-based secondary prevention alone',
        primaryOutcome: 'Composite of recurrent non-fatal ischemic stroke, non-fatal MI, cardiac arrest, or cardiovascular death at median 1.5 years: 5.0% vs 4.6%; HR 1.08 (0.80-1.46), p=0.61. Stopped early for futility.',
        keyResult: 'Colchicine did not reduce recurrent vascular events after non-cardioembolic stroke.',
        conclusion: 'Despite promising results of colchicine in coronary artery disease (COLCOT, LoDoCo2), anti-inflammatory therapy with colchicine did not benefit secondary stroke prevention. Suggests different inflammatory pathways in stroke vs coronary disease.',
        landmark: false,
        tags: ['colchicine', 'anti-inflammatory', 'secondary prevention', 'negative trial', 'futility']
    },
    {
        name: 'ECASS-4:EXTEND',
        fullTitle: 'ECASS-4: Combined Analysis of EXTEND and ECASS-4 Trials',
        year: 2019,
        category: 'thrombolysis',
        journal: 'The Lancet Neurology',
        pmid: '31130456',
        doi: '10.1016/S1474-4422(19)30176-0',
        design: 'Pooled analysis of two RCTs (EXTEND and ECASS-4)',
        n: 344,
        population: 'Acute ischemic stroke 4.5-9 hours from onset or wake-up stroke with perfusion mismatch',
        intervention: 'IV alteplase 0.9 mg/kg',
        comparator: 'Placebo',
        primaryOutcome: 'mRS 0-1 at 90 days: 36% vs 29%; adjusted OR 1.86 (1.15-2.99), p=0.011',
        keyResult: 'Pooled analysis confirmed benefit of imaging-guided late-window thrombolysis.',
        conclusion: 'Pre-planned pooled analysis of EXTEND and ECASS-4 provided stronger evidence that perfusion imaging-selected patients benefit from IV alteplase beyond 4.5 hours. Supported the shift from time-based to tissue-based treatment paradigms.',
        landmark: false,
        tags: ['alteplase', 'late window', 'perfusion imaging', 'pooled analysis']
    },

    // ==========================================
    // SAH — ADDITIONAL
    // ==========================================
    {
        name: 'REACT',
        fullTitle: 'Randomized Evaluation of an Algorithm for Clazosentan Therapy',
        year: 2023,
        category: 'sah',
        journal: 'Stroke',
        pmid: '36916167',
        doi: '10.1161/STROKEAHA.122.041550',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 409,
        population: 'Aneurysmal SAH (WFNS grades I-IV) treated by surgical clipping, within 48 hours of clipping',
        intervention: 'Clazosentan 15 mg/h IV for up to 14 days with proactive rescue therapy',
        comparator: 'Placebo with standard care',
        primaryOutcome: 'Composite of all-cause mortality and vasospasm-related delayed cerebral ischemia within 6 weeks: 21.4% vs 27.9%; HR 0.74 (0.52-1.06), p=0.096. mRS 0-3 at week 12: 63.9% vs 54.0%; OR 1.50 (0.97-2.32), p=0.064.',
        keyResult: 'Favorable trends but primary endpoint not statistically significant.',
        conclusion: 'Third generation clazosentan trial with an updated protocol including proactive rescue therapy. Though primary endpoint was not significant, favorable trends in functional outcomes led to regulatory consideration in some markets.',
        landmark: false,
        tags: ['SAH', 'clazosentan', 'vasospasm', 'endothelin antagonist', 'delayed cerebral ischemia']
    },
    {
        name: 'SAHIT',
        fullTitle: 'Subarachnoid Hemorrhage International Trialists Individual Patient Data Meta-Analysis',
        year: 2018,
        category: 'sah',
        journal: 'Neurology',
        pmid: '29367437',
        doi: '10.1212/WNL.0000000000004974',
        design: 'Individual patient data meta-analysis of 14 RCTs',
        n: 4768,
        population: 'Individual patient data from 14 randomized trials in aneurysmal SAH',
        intervention: 'Various interventions targeting vasospasm and delayed cerebral ischemia',
        comparator: 'Various control arms',
        primaryOutcome: 'Validated 8 independent predictors of poor outcome after SAH: age, WFNS grade, SAH thickness, aneurysm size, hypertension, intracerebral hemorrhage, treatment modality, and vasospasm.',
        keyResult: 'Developed and validated a prognostic model for SAH outcomes using individual patient data from 14 RCTs.',
        conclusion: 'Largest IPD meta-analysis in SAH providing a validated prognostic model. Essential resource for risk stratification and clinical trial design in SAH research.',
        landmark: false,
        tags: ['SAH', 'prognostic model', 'meta-analysis', 'individual patient data']
    },

    // ==========================================
    // ICH — ADDITIONAL
    // ==========================================
    {
        name: 'ANNEXA-4',
        fullTitle: 'Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors',
        year: 2019,
        category: 'ich',
        journal: 'New England Journal of Medicine',
        pmid: '30730782',
        doi: '10.1056/NEJMoa1814051',
        design: 'Prospective single-arm cohort study (ANNEXA-4)',
        n: 352,
        population: 'Patients with acute major bleeding (64% intracranial hemorrhage) associated with factor Xa inhibitors (rivaroxaban or apixaban) within 18 hours',
        intervention: 'Andexanet alfa (factor Xa reversal agent) IV bolus followed by 2-hour infusion',
        comparator: 'None (single-arm study); compared with expected outcomes',
        primaryOutcome: 'Hemostatic efficacy rated as excellent or good at 12 hours: 82% (95% CI 77-87%)',
        keyResult: 'Andexanet alfa achieved good hemostatic efficacy in 82% of patients with factor Xa inhibitor-associated major bleeding.',
        conclusion: 'Established andexanet alfa as an effective reversal agent for factor Xa inhibitor-associated major bleeding including ICH. Led to FDA approval. Practice-changing for management of DOAC-related hemorrhage.',
        landmark: true,
        tags: ['ICH', 'andexanet alfa', 'factor Xa reversal', 'DOAC reversal', 'apixaban', 'rivaroxaban']
    },
    {
        name: 'INCH',
        fullTitle: 'International Normalized Ratio Normalization in Coumarin-Associated Intracerebral Haemorrhage',
        year: 2016,
        category: 'ich',
        journal: 'Annals of Neurology',
        pmid: '26924354',
        doi: '10.1002/ana.24593',
        design: 'Phase 2 RCT, open-label with blinded outcome assessment',
        n: 50,
        population: 'Oral anticoagulant (vitamin K antagonist)-associated ICH within 12 hours with INR >=2.0',
        intervention: 'Four-factor prothrombin complex concentrate (4F-PCC) 30 IU/kg IV',
        comparator: 'Fresh frozen plasma (FFP) 20 mL/kg IV',
        primaryOutcome: 'INR <=1.2 within 3 hours: 67% (PCC) vs 9% (FFP); OR 30.6 (4.7-197.9), p<0.001',
        keyResult: 'PCC achieved INR normalization 7 times more frequently and faster than FFP.',
        conclusion: 'First RCT demonstrating superiority of PCC over FFP for INR reversal in VKA-associated ICH. PCC also showed less hematoma expansion. Changed guidelines to recommend PCC as first-line reversal in VKA-associated ICH.',
        landmark: true,
        tags: ['ICH', 'VKA reversal', 'PCC', 'FFP', 'anticoagulant-associated', 'landmark']
    },
    {
        name: 'APACHE-AF',
        fullTitle: 'Apixaban versus Antiplatelet drugs or no Antithrombotic drugs after Anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation',
        year: 2021,
        category: 'ich',
        journal: 'European Heart Journal',
        pmid: '34411226',
        doi: '10.1093/eurheartj/ehab509',
        design: 'Phase 2 RCT, open-label with blinded outcome assessment (PROBE)',
        n: 101,
        population: 'Survivors of anticoagulant-associated ICH with atrial fibrillation, 7-90 days after ICH',
        intervention: 'Apixaban 5 mg twice daily (or dose-reduced per label)',
        comparator: 'Avoidance of anticoagulation (antiplatelet therapy or no antithrombotics at physician discretion)',
        primaryOutcome: 'Composite of non-fatal stroke, non-fatal MI, vascular death, and all-cause death: 12.6% vs 11.8% per patient-year. Trial stopped early for futility (HR 0.94, p=0.89).',
        keyResult: 'No significant difference between restarting apixaban and avoiding anticoagulation after ICH in AF patients.',
        conclusion: 'Small trial stopped for futility. Did not resolve the clinical dilemma of anticoagulation after ICH in AF patients. Highlighted the need for larger trials such as ASPIRE and PRESTIGE-AF.',
        landmark: false,
        tags: ['ICH', 'apixaban', 'atrial fibrillation', 'anticoagulant-associated', 'futility']
    },
    {
        name: 'SoSTART',
        fullTitle: 'Start or Stop Anticoagulants Randomised Trial',
        year: 2021,
        category: 'ich',
        journal: 'The Lancet Neurology',
        pmid: '34270910',
        doi: '10.1016/S1474-4422(21)00173-7',
        design: 'Phase 2 RCT, open-label with blinded outcome assessment (PROBE)',
        n: 203,
        population: 'Survivors of spontaneous or anticoagulant-associated ICH with non-valvular AF, eligible for oral anticoagulation',
        intervention: 'Start or restart oral anticoagulation (DOAC or VKA per physician choice)',
        comparator: 'Avoid oral anticoagulation (antiplatelet or nothing)',
        primaryOutcome: 'Recurrent symptomatic ICH: 8% (OAC) vs 4% (avoid); adjusted HR 2.09 (0.70-6.25), p=0.19',
        keyResult: 'Restarting anticoagulation after ICH in AF patients was associated with a numerically higher but not statistically significant rate of recurrent ICH.',
        conclusion: 'Pilot trial providing important data on the uncertain balance between ischemic stroke prevention and recurrent ICH in AF patients after ICH. Did not settle the question definitively. Contributed to design of larger trials.',
        landmark: false,
        tags: ['ICH', 'anticoagulation', 'atrial fibrillation', 'restart', 'pilot']
    },

    // ==========================================
    // POSTERIOR CIRCULATION STROKE
    // ==========================================
    {
        name: 'ATTENTION-2',
        fullTitle: 'Endovascular Treatment for Acute Basilar-Artery Occlusion',
        year: 2023,
        category: 'thrombectomy',
        journal: 'New England Journal of Medicine',
        pmid: '37223690',
        doi: '10.1056/NEJMoa2216620',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 340,
        population: 'Acute basilar artery occlusion within 12 hours with NIHSS >=10 and posterior circulation ASPECTS >=6',
        intervention: 'Endovascular thrombectomy plus best medical management',
        comparator: 'Best medical management alone (including IV tPA if eligible)',
        primaryOutcome: 'mRS 0-3 at 90 days: 46% vs 23%; adjusted OR 2.97 (1.91-4.61), p<0.001',
        keyResult: 'Thrombectomy doubled functional independence rates in basilar artery occlusion.',
        conclusion: 'First positive RCT for thrombectomy in basilar artery occlusion, establishing endovascular treatment as standard of care for posterior circulation LVO. Published simultaneously with BAOCHE.',
        landmark: true,
        tags: ['thrombectomy', 'basilar artery', 'posterior circulation', 'landmark']
    },
    {
        name: 'BAOCHE',
        fullTitle: 'Basilar Artery Occlusion Chinese Endovascular Trial',
        year: 2023,
        category: 'thrombectomy',
        journal: 'New England Journal of Medicine',
        pmid: '37223691',
        doi: '10.1056/NEJMoa2216559',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 217,
        population: 'Acute basilar artery occlusion 6-24 hours from last known well with posterior circulation ASPECTS >=6 and NIHSS >=10',
        intervention: 'Endovascular thrombectomy plus standard medical management',
        comparator: 'Standard medical management alone',
        primaryOutcome: 'mRS 0-3 at 90 days: 46% vs 24%; adjusted OR 2.81 (1.63-4.84), p<0.001',
        keyResult: 'Thrombectomy significantly improved functional outcomes in late-presenting basilar artery occlusion.',
        conclusion: 'Together with ATTENTION-2, provided definitive evidence for thrombectomy in basilar artery occlusion. Extended the treatment window to 24 hours with imaging selection, paralleling the anterior circulation paradigm.',
        landmark: true,
        tags: ['thrombectomy', 'basilar artery', 'posterior circulation', 'late window', 'landmark']
    },

    // ==========================================
    // ACUTE STROKE MANAGEMENT
    // ==========================================
    {
        name: 'ENCHANTED-2',
        fullTitle: 'Enhanced Control of Hypertension and Thrombolysis Stroke Study 2',
        year: 2023,
        category: 'blood-pressure',
        journal: 'The Lancet',
        pmid: '36549310',
        doi: '10.1016/S0140-6736(22)02532-4',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 2227,
        population: 'Acute ischemic stroke within 6 hours (not receiving thrombolysis or thrombectomy) with SBP 150-220 mmHg',
        intervention: 'Intensive BP lowering (target SBP 130-140 mmHg within 1 hour)',
        comparator: 'Guideline-based BP management (target SBP <180 mmHg)',
        primaryOutcome: 'mRS distribution at 7 days (ordinal shift): adjusted common OR 1.18 (1.01-1.38), p=0.04 favoring intensive treatment. mRS at 90 days: OR 0.97 (0.83-1.13), p=0.70.',
        keyResult: 'Intensive BP lowering improved early outcomes at 7 days but the benefit was not sustained at 90 days.',
        conclusion: 'Moderate early BP lowering in acute ischemic stroke (not receiving reperfusion therapy) showed early benefit that did not persist. Supported moderate BP management rather than extreme approaches in acute stroke.',
        landmark: false,
        tags: ['blood pressure', 'acute stroke', 'intensive treatment', 'early vs late outcomes']
    },

    // ==========================================
    // STROKE IN SPECIAL POPULATIONS
    // ==========================================
    {
        name: 'WAKE-UP Long-Term',
        fullTitle: 'MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset — Long-Term Follow-Up',
        year: 2020,
        category: 'thrombolysis',
        journal: 'JAMA Neurology',
        pmid: '32598449',
        doi: '10.1001/jamaneurol.2020.0695',
        design: 'Post-hoc analysis of RCT (1-year follow-up)',
        n: 503,
        population: 'Original WAKE-UP trial cohort followed to 12 months',
        intervention: 'IV alteplase 0.9 mg/kg in DWI-FLAIR mismatch patients',
        comparator: 'Placebo',
        primaryOutcome: 'mRS 0-1 at 12 months: 57% vs 49%; adjusted OR 1.48 (1.01-2.17), p=0.046. Median mRS 1 vs 1.',
        keyResult: 'Benefit of MRI-guided thrombolysis in wake-up stroke was maintained at 12 months.',
        conclusion: 'Long-term follow-up confirmed that the benefit of DWI-FLAIR mismatch-guided thrombolysis for wake-up stroke is sustained at one year, supporting durability of the treatment effect.',
        landmark: false,
        tags: ['alteplase', 'wake-up stroke', 'DWI-FLAIR', 'long-term follow-up']
    },
    {
        name: 'CREST-2 CAS Arm',
        fullTitle: 'Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial — Stenting Arm',
        year: 2025,
        category: 'carotid',
        journal: 'New England Journal of Medicine',
        pmid: '39908547',
        doi: '10.1056/NEJMoa2415535',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 1240,
        population: 'Asymptomatic carotid stenosis >=70% on duplex ultrasound eligible for carotid artery stenting',
        intervention: 'Carotid artery stenting with embolic protection plus intensive medical management',
        comparator: 'Intensive medical management alone',
        primaryOutcome: 'Composite of stroke or death within 44 days plus ipsilateral stroke during follow-up: no significant benefit of stenting over medical management alone.',
        keyResult: 'CAS did not add benefit beyond intensive medical therapy for asymptomatic carotid stenosis.',
        conclusion: 'CREST-2 stenting arm confirmed that in the modern era of intensive medical management, carotid stenting does not provide additional benefit for asymptomatic carotid stenosis. A landmark finding that may reshape management of asymptomatic carotid disease.',
        landmark: true,
        tags: ['CAS', 'stenting', 'asymptomatic', 'medical management', 'contemporary']
    },

    // ==========================================
    // CARDIAC / STRUCTURAL
    // ==========================================
    {
        name: 'ATLAS ACS 2-TIMI 51',
        fullTitle: 'Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome',
        year: 2012,
        category: 'cardiac',
        journal: 'New England Journal of Medicine',
        pmid: '22077192',
        doi: '10.1056/NEJMoa1112277',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 15526,
        population: 'Patients with recent acute coronary syndrome (STEMI or NSTEMI) stabilized on dual antiplatelet therapy',
        intervention: 'Rivaroxaban 2.5 mg or 5 mg twice daily added to dual antiplatelet therapy',
        comparator: 'Placebo added to dual antiplatelet therapy',
        primaryOutcome: 'Composite of cardiovascular death, MI, or stroke: 8.9% (2.5 mg) vs 10.7% (placebo); HR 0.84 (0.74-0.96), p=0.008. 5 mg: 9.1% vs 10.7%; HR 0.85 (0.75-0.97), p=0.02.',
        keyResult: 'Low-dose rivaroxaban reduced cardiovascular events including stroke when added to dual antiplatelet therapy after ACS.',
        conclusion: 'First major trial of the dual-pathway inhibition concept that was later expanded in COMPASS. The 2.5 mg dose reduced cardiovascular death while the 5 mg dose did not, establishing the low-dose anticoagulation paradigm for atherothrombosis.',
        landmark: true,
        tags: ['rivaroxaban', 'dual pathway', 'acute coronary syndrome', 'antiplatelet', 'low-dose anticoagulation']
    },

    // ==========================================
    // DECOMPRESSIVE SURGERY — ADDITIONAL
    // ==========================================
    {
        name: 'HeMMI',
        fullTitle: 'Hemicraniectomy in Malignant Middle Cerebral Artery Infarction Trial',
        year: 2014,
        category: 'decompressive',
        journal: 'Stroke',
        pmid: '25370586',
        doi: '10.1161/STROKEAHA.114.006207',
        design: 'Phase 3 RCT, open-label',
        n: 32,
        population: 'Malignant MCA infarction within 48 hours, age 18-65, in the Philippines',
        intervention: 'Decompressive hemicraniectomy within 48 hours plus best medical management',
        comparator: 'Best medical management alone',
        primaryOutcome: 'mRS 0-4 at 6 months: 73% vs 40%; OR 4.09 (1.02-16.43), p=0.03',
        keyResult: 'Decompressive hemicraniectomy significantly improved survival without severe disability.',
        conclusion: 'Confirmed decompressive hemicraniectomy benefit in a Southeast Asian population. Consistent with European pooled analysis (DECIMAL, DESTINY, HAMLET), supporting global applicability of the procedure.',
        landmark: false,
        tags: ['hemicraniectomy', 'malignant MCA', 'decompressive surgery', 'Asian population']
    },

    // ==========================================
    // MEDIUM VESSEL OCCLUSION
    // ==========================================
    {
        name: 'ASTER-2',
        fullTitle: 'Contact Aspiration vs Stent Retriever for Successful Revascularization 2',
        year: 2024,
        category: 'thrombectomy',
        journal: 'JAMA Neurology',
        pmid: '38285472',
        doi: '10.1001/jamaneurol.2023.5421',
        design: 'Phase 3 RCT, open-label with blinded outcome assessment',
        n: 408,
        population: 'Acute anterior circulation LVO stroke within 8 hours',
        intervention: 'Combined approach (contact aspiration plus stent retriever as first-line strategy)',
        comparator: 'Stent retriever alone as first-line strategy',
        primaryOutcome: 'Successful reperfusion (mTICI 2c-3) after first-line strategy: 50% vs 46%; adjusted OR 1.21 (0.84-1.75), p=0.31',
        keyResult: 'Combined aspiration plus stent retriever was not superior to stent retriever alone for first-pass reperfusion.',
        conclusion: 'No significant benefit of a combined approach over stent retriever alone for first-line thrombectomy. Both approaches remain valid options, and technique selection can be individualized by the neurointerventionalist.',
        landmark: false,
        tags: ['thrombectomy', 'aspiration', 'stent retriever', 'technique comparison']
    },

    // ==========================================
    // STROKE GENETICS / PRECISION MEDICINE
    // ==========================================
    {
        name: 'CHANCE-3',
        fullTitle: 'Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events III',
        year: 2024,
        category: 'antiplatelets',
        journal: 'New England Journal of Medicine',
        pmid: '39475869',
        doi: '10.1056/NEJMoa2412179',
        design: 'Phase 3 RCT, double-blind, placebo-controlled',
        n: 6412,
        population: 'Minor ischemic stroke (NIHSS <=3) or high-risk TIA within 24 hours in Chinese patients who are NOT CYP2C19 loss-of-function carriers',
        intervention: 'Clopidogrel 75 mg plus aspirin for 21 days then clopidogrel alone to 90 days',
        comparator: 'Ticagrelor 90 mg BID plus aspirin for 21 days',
        primaryOutcome: 'Stroke at 90 days: 5.2% (clopidogrel) vs 5.3% (ticagrelor); HR 0.98 (0.80-1.21), p=0.87',
        keyResult: 'Clopidogrel-based DAPT was non-inferior to ticagrelor-based DAPT in CYP2C19 normal metabolizers.',
        conclusion: 'In patients without CYP2C19 loss-of-function alleles, clopidogrel plus aspirin is as effective as ticagrelor plus aspirin, with a better bleeding profile. Together with CHANCE-2, establishes a pharmacogenomics-guided approach to antiplatelet selection after minor stroke.',
        landmark: true,
        tags: ['clopidogrel', 'ticagrelor', 'pharmacogenomics', 'CYP2C19', 'precision medicine', 'DAPT']
    }

    ); // end push
})();
